Faculty: Federico Alberici, MD, PhD

Faculty: Anastasia Liossatou, PhD, RN

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Steven Fishbane, MD

Faculty: Nancy Helou, PhD

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Steven Fishbane, MD

Faculty: Nancy Helou, PhD

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Brendon Neuen, MBBS, PhD

Faculty: Katherine Tuttle, MD

A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may expand treatment considerations for patients with chronic kidney disease (CKD), including those without diabetes. Through expert analysis of key studies and a patient perspective, the faculty explore the evolving cardiorenal landscape, practical implications for clinical practice, and opportunities to address persistent unmet needs across the CKD spectrum.

Faculty: Jose Rubio, MD

Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse effects that affect adherence. Emerging evidence supports a role for muscarinic M₁/M₄ receptor dysfunction in schizophrenia, leading to the development of therapies with mechanisms distinct from dopamine blockade. This Chairperson’s Perspective reviews clinical data for xanomeline–trospium and discusses practical considerations for integrating muscarinic therapies into practice, including patient selection, treatment sequencing, dosing, and management of gastrointestinal and autonomic adverse effects. Are you prepared to incorporate muscarinic agents into the treatment of schizophrenia? Tune in for an overview of the latest data.

Guest: Emma Guttman, MD, PhD

Emma Guttman, MD, PhD, discusses the disconnect that sometimes exists in atopic dermatitis between clinical trials and real-world situations.

Faculty: Andrea Lora Kossler, MD, FACS

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Kimberly Cockerham, MD

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.

Faculty: Prem S. Subramanian, MD, PhD

Faculty: Andrea Lora Kossler, MD, FACS

Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our experts streamline clinic workflows, reduce infusion burden, and coordinate care to improve patient outcomes.